ARS Pharmaceuticals Inc (NAS:SPRY)
$ 12.96 0.15 (1.17%) Market Cap: 1.26 Bil Enterprise Value: 1.04 Bil PE Ratio: 0 PB Ratio: 5.77 GF Score: 22/100

Silverback Therapeutics Inc Strategic Prioritization and Corporate Update Call Transcript

Mar 31, 2022 / 09:00PM GMT
Operator

Welcome to the Silverback Therapeutics update on the strategic priorities. (Operator Instructions) I would now like to hand the conference over to Jonathan Piazza, Chief Financial Officer of Silverback Therapeutics. The floor is yours.

Jonathan Piazza
Silverback Therapeutics Inc. - CFO

Thank you, operator. Good afternoon, and welcome to the Silverback webcast to discuss an update on our strategic priorities. Following market close today, March 31, we filed our Form 10-K and issued a press release detailing our strategic reprioritization and our financial results for the fourth quarter and full year ended 2021.

Starting on slide 2, you will be making forward-looking statements in this presentation, including statements regarding our business and the expected timing and impact of future events. Filings made with the Securities and Exchange Commission, including 10-K and 10-Q reports describe various risks relating to these statements. You are cautioned not to place undue reliance on these forward-looking statements, and Silverback disclaims any

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot